Double mutant DNMT3A AML: a unique subtype experiencing increased DNA damage and poor prognosis

Authors: Boertjes, Emma L., Massaar, Sanne, Zeilemaker, Annelieke, Konijnenburg, Jolinda, Rijken, Melissa, Kavelaars, François G., Grob, Tim, Versluis, Jurjen, Löwenberg, Bob, Valk, Peter J. M., Sanders, Mathijs A. ^∗

Source: In Blood Advances 25 March 2025 9(6):1344-1355

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML

Authors: Vonk, Christian M. ¹, Grob, Tim ¹, Rijken, Melissa ¹, Kavelaars, François G. ¹, Konijnenburg, Jolinda M. L. ¹, Ossenkoppele, Gert J. ², Manz, Markus G. ³, Havelange, Violaine ⁴, Fløisand, Yngvar ^{5, 6}, Löwenberg, Bob ¹, Valk, Peter J. M. ^{1, ∗}

Source: In Blood Advances 11 March 2025 9(5):1069-1077

STAG2 mutations reshape the cohesin-structured spatial chromatin architecture to drive gene regulation in acute myeloid leukemia

Authors: Fischer, Alexander ^{1, 2}, Hernández-Rodríguez, Benjamín ³, Mulet-Lazaro, Roger ^{4, 5}, Nuetzel, Margit ¹, Hölzl, Fabian ², van Herk, Stanley ^{4, 5}, Kavelaars, François G. ⁴, Stanewsky, Hanna ¹, Ackermann, Ute ¹, Niang, Amadou H. ³, Diaz, Noelia ^{3, 9}, Reuschel, Edith ⁶, Strieder, Nicholas ², Hernández-López, Inmaculada ², Valk, Peter J.M. ⁴, Vaquerizas, Juan M. ^{3, 7, 8}, Rehli, Michael ^{1, 2, 10}, Delwel, Ruud ^{4, 5, 10}, Gebhard, Claudia ^{2, 10, 11, ∗}

Source: In Cell Reports 27 August 2024 43(8)

Detecting measurable residual disease beyond 10−4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL

Authors: Hengeveld, Paul J., van der Klift, Michèle Y., Kolijn, P. Martijn, Davi, Frédéric, Kavelaars, François G., de Jonge, Evert, Robrecht, Sandra, Assmann, Jorn L. J. C., van der Straten, Lina, Ritgen, Matthias, Westerweel, Peter E., Fischer, Kirsten, Goede, Valentin, Hallek, Michael, Levin, Mark-David ^∗, Langerak, Anton W. ^{∗, ∗}

Source: In Blood 2 February 2023 141(5):519-528

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Authors: Grob, Tim ^*, Al Hinai, Adil S.A. ^*, Sanders, Mathijs A., Kavelaars, François G., Rijken, Melissa, Gradowska, Patrycja L., Biemond, Bart J., Breems, Dimitri A., Maertens, Johan, van Marwijk Kooy, Marinus, Pabst, Thomas, de Weerdt, Okke, Ossenkoppele, Gert J., van de Loosdrecht, Arjan A., Huls, Gerwin A., Cornelissen, Jan J., Beverloo, H. Berna, Löwenberg, Bob, Jongen-Lavrencic, Mojca, Valk, Peter J.M. ^*

Source: In Blood 14 April 2022 139(15):2347-2354

Risk Stratification in Older Intensively Treated Patients With AML.

Authors: Versluis, Jurjen, Metzner, Marlen, Wang, Ariel, Gradowska, Patrycja, Thomas, Abin, Jakobsen, Niels Asger, Kennedy, Alison, Moore, Rachel, Boertjes, Emma, Vonk, Christian M., Kavelaars, Francois G., Rijken, Melissa, Gilkes, Amanda, Schwab, Claire, Beverloo, H. Berna, Manz, Markus, Visser, Otto, Van Elssen, Catharina H.M.J., de Weerdt, Okke, Tick, Lidwine W.

Source: Journal of Clinical Oncology; 12/1/2024, Vol. 42 Issue 34, p4084-4094, 13p

AML-279 Molecularly-Defined De Novo and Secondary Acute Myeloid Leukemia Are Biologically and Clinically Different Entities

Authors: Boertjes, Emma, Hinai, Adil Al, Stoetman, Elodie, Compagne, Kyra G., Grob, Tim, Kavelaars, Francois G., Rijken, Melissa, Sanders, Mathijs, Beverloo, Berna H., Löwenberg, Bob, Valk, Peter J.M.

Source: In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S232-S232

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML

Authors: Sanders, Mathijs A. ^*, Chew, Edward ^*, Flensburg, Christoffer, Zeilemaker, Annelieke, Miller, Sarah E., al Hinai, Adil S., Bajel, Ashish, Luiken, Bram, Rijken, Melissa, Mclennan, Tamara, Hoogenboezem, Remco M., Kavelaars, François G., Fröhling, Stefan, Blewitt, Marnie E., Bindels, Eric M., Alexander, Warren S., Löwenberg, Bob, Roberts, Andrew W., Valk, Peter J.M., Majewski, Ian J.

Source: In Blood 4 October 2018 132(14):1526-1534

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA.

Authors: Vonk, Christian M., Boertjes, Emma L., Kavelaars, Francois G., Rijken, Melissa, Konijnenburg, Jolinda M. L., Cromwell, Roxanne E., Löwenberg, Bob, Grob, Tim, Valk, Peter J. M.

Source: HemaSphere; Aug2024, Vol. 8 Issue 8, p1-3, 3p

AML-464 Advantages and Prognostic Value of Next-Generation Sequencing–Based Mutant NPM1 Measurable Residual Disease Detection in AML

Authors: Vonk, Christian M., Grob, Tim, Rijken, Melissa, Kavelaars, Francois G., Konijnenburg, Jolinda M.L., Löwenberg, Bob, Valk, Peter J.M.

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S314-S315

Advantages and Prognostic Value of Next-Generation Sequencing–Based Mutant NPM1 Measurable Residual Disease Detection in AML

Authors: Vonk, Christian M., Grob, Tim, Rijken, Melissa, Kavelaars, Francois G., Konijnenburg, Jolinda M.L., Löwenberg, Bob, Valk, Peter J.M.

Source: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S171-S171

Poster: AML-279 Molecularly-Defined De Novo and Secondary Acute Myeloid Leukemia Are Biologically and Clinically Different Entities

Authors: Boertjes, Emma, Hinai, Adil Al, Stoetman, Elodie, Compagne, Kyra G., Grob, Tim, Kavelaars, Francois G., Rijken, Melissa, Sanders, Mathijs, Beverloo, Berna H., Löwenberg, Bob, Valk, Peter J.M.

Source: Clinical lymphoma, myeloma & leukemia. 22(S2):S132-S132

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100172885382.0x000001&indx=1&recIds=ETOCvdc_100172885382.0x000001

DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia

Authors: Cucchi, David G.J., Vonk, Christian M., Rijken, Melissa, Kavelaars, François G., Merle, Pauline A., Verhoef, Elvira, Venniker-Punt, Bianca, Kwidama, Zinia J., Gradowska, Patrycja, Löwenberg, Bob, Janssen, Jeroen J.W.M., Cloos, Jacqueline, Valk, Peter J.M. ^*

Source: In Blood Advances 9 November 2021 5(21):4476-4479

RUNX1 germline variants in RUNX1-mutant AML: how frequent?

Authors: Ernst, Martijn P.T., Kavelaars, François G., Löwenberg, Bob, Valk, Peter J.M. ^{*, **}, Raaijmakers, Marc H.G.P. ^{*, *}

Source: In Blood 11 March 2021 137(10):1428-1431

Protein functionality as a potential bottleneck for somatic revertant variants

Authors: Kaiser, Fabian M.P., Reisli, Ismail, Pico-Knijnenburg, Ingrid, Langerak, Anton W., Kavelaars, François G., Artac, Hasibe, IJspeert, Hanna, van der Burg, Mirjam

Source: In The Journal of Allergy and Clinical Immunology January 2021 147(1):391-393

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Clonal Evolution of Multiple Myeloma in Patients from Diagnosis to First Relapse, Who Were Treated in Subsequent Clinical Trials

Authors: Duin, Mark van ^*, Broijl, Annemiek ^*, Koenders, Jasper ^*, Zweegman, Sonja ^*, Minnema, Monique C., Kavelaars, Francois G. ^*, Hoogenboezem, Remco ^*, Nasserinejad, Kazem ^*, Boccadoro, Mario, Valk, Peter, Sonneveld, Pieter

Source: In Blood 13 November 2019 134 Supplement 1:1798-1798

Archived Bone Marrow Smears Are an Excellent Source for NGS-Based Mutation Detection in Acute Myeloid Leukemia

Authors: Al Hinai, Adil S.A. ^*, Kavelaars, Francois G. ^*, Rijken, Melissa ^*, Grob, Tim ^*, Gussinklo, Kirsten ^*, Zeilemaker, Annelieke ^*, Erpelinck-Verschueren, Claudia ^*, Sanders, Mathijs A. ^*, van Lom, Kirsten ^*, Valk, Peter J.M.

Source: In Blood 29 November 2018 132 Supplement 1:2783-2783

This result is not displayed to guests.
Login for full access.